Elsevier adds 43 million Enamine make-on-demand compounds to Reaxys to accelerate chemistry R&D

Contributed by: Agility PR Solutions

Logo

Tags

Elsevier

Reaxys

More Like This

Enamine and BioSolveIT Embark on Exclusive Partnership

Elsevier and Iktos logos

Elsevier and Iktos partner to deliver an AI-driven synthetic chemistry platform for drug discovery

PR Newswire associated0

Merck Launches First Ever AI Solution to Integrate Drug Discovery and Synthesis

Advanced Manufacturing, Global Reach, and Streamlined Services — Asymchem Impresses at CPHI Milan 2024

PR Newswire associated0

Cambrex Announces Strategic Agreement with Lilly to Support Biotech Collaborator Manufacturing

ChemPartner Unveils Highly Anticipated Biology Database

Prepaire Labs is a pioneering healthcare technology company focused on revolutionizing drug discovery and precision medicine. Through the integration of deep learning and biology, Prepaire Labs builds predictive models grounded in genetic, phenotypic, and clinical data. These models form a view to the underlying architecture and biology of diseases. Prepaire Labs utilizes patient-derived induced pluripotent stem cells (iPSCs), genome editing, high-content cellular phenotyping, and machine learning to create in vitro disease models for increased predictability of human clinical outcomes. A state-of-the-art BSL3 lab is opening in May 2024, located at Masdar City, Abu Dhabi, UAE. This will serve as the new fully automated LAAS (Lab As A Service) hub and provide clinical trials on a chip using latest microfluidic devices combined with the ability to print organoid bio-networks. Visit www.prepaire.com to learn more. (Photo: Business Wire)

Chemify Partners with Prepaire Labs to Apply Ground-breaking Chemistry AI-Robotics to Radically Accelerate the Discovery of Non-Addictive Opioids

Asymchem’s Fully Automated Peptide Production Lines Set New Benchmarks as Large-Scale Capacity Continues to Grow